



Published in final edited form as:

J Clin Outcomes Manag. 2013 November 1; 20(11): 513–528.

Circadian Rhythm Sleep Disorders

Min Ju Kim, M.D.^{1,2}, Jung Hie Lee, M.D.^{1,3}, and Jeanne F. Duffy, M.B.A., Ph.D.^{1,*}

¹Division of Sleep Medicine, Department of Medicine, Brigham and Women's Hospital and Division of Sleep Medicine, Harvard Medical School, Boston, MA USA

²Department of Neurology, Howard OsanDongtan Hospital, Osan, Korea

³Department of Psychiatry, Kangwon National University Hospital, Chunchon, South Korea

Abstract

Objective—To review circadian rhythm sleep disorders, including underlying causes, diagnostic considerations, and typical treatments.

Methods—Literature review and discussion of specific cases.

Results—Survey studies ^{1,2} suggest that up to 3% of the adult population suffers from a circadian rhythm sleep disorder (CRSD). However, these sleep disorders are often confused with insomnia, and an estimated 10% of adult and 16% of adolescent sleep disorders patients may have a CRSD ³⁻⁶. While some CRSD (such as jet lag) can be self-limiting, others when untreated can lead to adverse medical, psychological, and social consequences. The International Classification of Sleep Disorders classifies CRSD as dyssomnias, with six subtypes: Advanced Sleep Phase Type, Delayed Sleep Phase Type, Irregular Sleep Wake Type, Free Running Type, Jet Lag Type, and Shift Work Type. The primary clinical characteristic of all CRSD is an inability to fall asleep and wake at the desired time. It is believed that CRSD arise from a problem with the internal biological clock (circadian timing system) and/or misalignment between the circadian timing system and the external 24-hour environment. This misalignment can be the result of biological and/or behavioral factors. CRSD can be confused with other sleep or medical disorders.

Conclusions—Circadian rhythm sleep disorders are a distinct class of sleep disorders characterized by a mismatch between the desired timing of sleep and the ability to fall asleep and remain asleep. If untreated, CRSD can lead to insomnia and excessive daytime sleepiness, with negative medical, psychological, and social consequences. It is important for physicians to recognize potential circadian rhythm sleep disorders so that appropriate diagnosis, treatment, and referral can be made.

Introduction

Humans, like most other organisms, have near-24-hour rhythms in many aspects of physiology and behavior, including the daily cycle of sleep and wakefulness. These circadian rhythms are not a simple response to environmental changes associated with day

*Address for Correspondence: Jeanne F. Duffy, Division of Sleep Medicine, 221 Longwood Avenue, BLI438, Boston, MA 02115 USA, jduffy@hms.harvard.edu, Tel : 617-732-7995.

and night, but are intrinsic to the organism. While there are circadian rhythms present in individual cells, overall coordination of the circadian system is driven by the suprachiasmatic nuclei in the hypothalamus⁷⁻¹³.

As the term “circadian” implies (circa=approximately, dies=day), these rhythms are near 24 hours in length, but in most individuals the circadian period (cycle length) is not exactly 24 hours. In specialized laboratory studies designed to measure circadian period in humans, the range is reported to be from about 23.5 to 24.5 hours in sighted individuals¹⁴⁻²⁰. These near-24-hour rhythms are entrained (synchronized) to the 24-hour day by regular exposure to light during the daytime and darkness at night. This is achieved because the circadian timing system responds to light in a phase-dependent manner. This means that the same light experienced at one time of day does not have the same effect on the circadian system as the exact same light (intensity, duration, wavelength) experienced at a different time of day. Light exposure in the late biological night and early biological morning (the hours surrounding typical wake time for the individual) produces phase advance shifts (shifts of the circadian system to an earlier hour), light exposure in the middle of the biological day produces no or very small phase shifts, and light exposure in the late biological evening and early biological night (the hours surrounding typical bed time for the individual) produces phase delay shifts (shifts in the timing of rhythms to a later hour)²¹⁻²⁶. When stably entrained, the individual's underlying circadian rhythm in light sensitivity will be aligned such that it produces a daily phase shift to light exposure that equals the difference in period between the individual's circadian period and 24 hours. Therefore, an individual with a 24.2-hour circadian period will be aligned such that they achieve an average daily phase advance shift of 0.2 hours from light exposure in the morning, allowing them to remain stably entrained¹⁵.

One of the many daily rhythms generated by the circadian timing system includes a rhythm in sleep-wake propensity²⁷⁻³⁰. This rhythm is timed such that the greatest drive for wakefulness occurs just before usual bedtime, and the greatest drive for sleep occurs in the latter part of the night, around the time of usual awakening^{29, 30}. This circadian rhythm in sleep-wake propensity interacts with a sleep-wake homeostatic process, a process that reflects recent sleep-wake history and produces greater sleep drive with longer wake durations³¹. When these two sleep regulatory systems are in balance, they allow for a consolidated sleep episode at night and a long and consolidated wake episode during the day, something routinely experienced by adult humans but rare in most other species³². However, alterations to either one of these processes, or to the interaction between them, can result in a sleep disorder.

The circadian rhythm sleep disorders (CRSD) arise when the desired timing of sleep does not match the underlying circadian rhythm in sleep propensity. Thus, the individual is attempting to sleep when sleep is difficult or impossible, resulting in a persistent or recurrent pattern of sleep disturbance³³. The underlying cause of this mis-match may be due to biological or behavioral reasons. For example, some feature of the circadian system itself may predispose the individual to a circadian rhythm sleep disorder. A circadian period that is much shorter or longer than usual is one example where a biological cause can lead to a circadian rhythm disorder. In such cases, the period difference between the underlying

circadian system and the 24-hour world in which the patient lives may be so large that it is difficult to achieve the daily circadian phase resetting required to remain synchronized. An altered circadian response to entraining signals from the environment (such as light) that normally synchronizes the circadian system to the 24-hour solar day may also lead to a circadian rhythm disorder. For example, a reduced responsiveness to light may produce daily phase resetting that is of insufficient magnitude to allow for stable entrainment³⁴⁻³⁷.

Because many behaviors can influence the circadian timing system, they can contribute to mis-matches between sleep timing and the rhythm in sleep propensity. The most likely of these behaviors to have a strong impact on the circadian system is the exposure to light and darkness. As noted above, the timing of light exposure is critical to the impact of that light on the circadian system, and the overall pattern of daily exposure to light and darkness (including the intensity and wavelength of light exposure) can determine whether stable entrainment is achieved, or instead whether the light-dark exposure works against stable entrainment and contributes to difficulty sleeping when desired. For example, most individuals have a circadian period longer than 24 hours, and require morning light exposure to achieve a daily phase advance shift in order to remain entrained to the 24-hour day¹⁵. If sufficient (in terms of intensity and/or duration) morning or daytime light exposure is not obtained on a regular basis, the circadian system may begin to drift out of synch with clock time, leading to a circadian rhythm disorder^{38, 39}. Similarly, excessive evening light exposure on a regular basis may cause shifts of the circadian system to a later time, and these shifts may then not be counteracted with sufficient shifts to an earlier hour from morning light exposure, leading the circadian system to become out of synch with clock time⁴⁰⁻⁴³.

Issues related to poor sleep hygiene can also contribute to the development of a CRSD. For example, an irregular sleep-wake schedule (bedtimes and wake times varying by hours from one day to another) typically is also associated with irregular light-dark exposure. Without regular light exposure to entrain the circadian system, a circadian rhythm sleep disorder may develop. Individuals with flexible schedules who have an opportunity to nap during the day and opportunities to “sleep in” may also be prone to developing CRSD, due to their greater opportunity to pursue poor sleep hygiene practices.

Circadian rhythm sleep disorders can also arise when the circadian system has a normal period and entrainment response, but the individual abruptly changes their sleep timing. This occurs in shift workers when they change shift timing (and therefore must also change their sleep timing), and also occurs when an individual travels rapidly across multiple time zones. In both cases, the circadian timing system cannot adapt quickly to the new schedule, resulting in a CRSD that may be transient or persistent.

Circadian Rhythm Sleep Disorder Types

The International Classification of Sleep Disorders (ICSD-2) suggests classification of CRSD into six distinct types (see Table 1). These include: 1) delayed sleep phase type, 2) advanced sleep phase type, 3) irregular sleep wake phase type, 4) free-running type, 5) jet lag type, and 6) shift work type.³³ The term, ‘type’ in this classification is used

interchangeably with the earlier terms 'syndrome' or 'disorder'. A brief description of each of these six types follows.

Individuals with Delayed Sleep Phase Type [or delayed sleep phase syndrome, herein called DSPS] are characterized by sleep onset and offset several hours later than desired and also later compared to normal individuals. Individuals with DSPS have a very prolonged sleep latency when they attempt to fall asleep at a conventional time, and similarly have great difficulty to arise when they try to get up at a conventional time. When allowed to sleep unconstrained by social requirements, they show normal sleep architecture and sleep duration. DSPS is the most frequent type of CRSD seen by the clinician, and often first occurs in adolescence or young adulthood⁴⁴. Individuals with DSPS often have difficulty with school or employment, because they have difficulty falling asleep at an early enough time to be able to obtain sufficient sleep. These individuals often remain awake until very late at night, and consequently have difficulty waking up in the morning. This leads to tardiness and/or to poor performance and even falling asleep at work or school due to daytime sleepiness. In some cases, patients whose DSPS remains untreated or fails to respond to treatment may develop other psychological disorders⁴⁵.

Advanced Sleep Phase Type (ASPS) individuals experience problems opposite to those of DSPS individuals. They have regular sleep-wake patterns but with much earlier than desired (or conventional) sleep onset and offset times, but with normal sleep durations. These individuals typically do not have the same occupational consequences that DSPS patients do, and thus are less likely to be seen by physicians. In extreme cases, patients with ASPS may seek help when they have difficulty remaining awake in the evening for social events or to spend time with family. ASPS is more likely to be observed in the elderly than in young adults^{3, 46}.

The CRSD Irregular Sleep Wake Phase Type is characterized by a normal 24-hour sleep duration, but disruption and fragmentation of the sleep-wake cycle. These individuals suffer from disorganized and fragmented sleep. This type is most frequently seen in institutionalized patients, who may spend many hours per day in bed and who are not exposed to a strong light-dark cycle.

Free-Running Type, also known as non-24-hour sleep-wake syndrome, hypernycthemeral syndrome, or non-entrained type, is characterized by a gradual delay of sleep onset time from one day to the next, so that sleep begins to occur during the daytime hours and then eventually drifts back into the night (and around to the day again). Patients with DSPS may transition to this type if untreated. In rarer cases, the sleep onset time moves earlier from one day to the next (an extension of ASPS rather than DSPS). By definition, patients with Free-Running Type have experienced a failure or lack of ability of their circadian system to be entrained to the 24-hour day. This syndrome occurs in many totally blind people whose neural light entrainment structures are damaged^{34, 47}, but occurs in sighted individuals as well.

Individuals who cross multiple time-zones may experience Jet Lag Type, which occurs because the circadian timing system is set to the home time zone and cannot reset to the new

time zone quickly upon arrival. The greater the difference from the home time zone, the more likely there will be jet lag, and the longer it will take to fully adjust. In many cases, jet lag is exacerbated by the effects of sleep loss that often accompany long-distance travel. For most people this is a self-resolving problem. However, for individuals who must travel frequently for work, jet lag can be a more persistent problem. In such cases, the daytime sleepiness, gastrointestinal symptoms, and sleep loss associated with jet lag⁴⁸ can lead to short-term (safety issues associated with daytime sleepiness, neurocognitive deficits associated with sleep loss and attempting to be awake at a biologically inappropriate times)^{49, 50} problems, and there is even evidence that there are long-term health consequence of repeated jet lag in airline flight crews^{51, 52}.

Shift work disorder is experienced by many of the estimated 9% of Americans (12.5 million) who work on the night shift or on irregular/rotating shift schedules that include overnight work hours⁵³⁻⁵⁵. In such cases, the circadian system of the worker does not adjust to the work schedule, leading to drowsiness during night work and difficulty attempting to sleep during the day. Night shift workers have shorter sleep durations on average than day or evening shift workers because they are attempting to sleep at a biologically inappropriate time, and as a consequence are unable to remain asleep. They also typically attempt to sleep following work (as opposed to just before starting work as most day workers do), and thus begin each night of work after insufficient sleep and many hours of wakefulness. Because of this, night work is associated with an increased risk of occupational⁵⁶⁻⁶³ and motor vehicle accidents (especially on the way home from work)^{59, 60, 63-72}. Shift work disorder is typically relieved after the patient resumes a day-work, night-sleep schedule, but for patients who work regular night shifts, or who work rotating shifts, the symptoms persist. Shift work disorder can also impact individuals with early shift start times because many such individuals find it difficult to go to bed early enough to obtain sufficient sleep. Chronic shift work increases the risk of myocardial infarction⁷³, cardiovascular disease⁷³⁻⁷⁷, GI disorders^{63, 78, 79}, metabolic syndrome⁸⁰⁻⁸⁷, and cancers⁸⁸⁻⁹⁶.

If untreated, CRSD can lead to physical, psychological and social stresses. Insufficient sleep, a consequence of many CRSD, is recognized as a contributing factor to a number of health problems, including obesity, cardiovascular disease⁹⁷, altered glucose metabolism⁹⁸⁻¹⁰², and immune dysfunction¹⁰³⁻¹⁰⁸. CRSD may also lead to greater accident risk, due to daytime drowsiness and/or attempting to perform at an adverse biological time. Thus, while most of the CRSD do not impact large numbers of patients, they can have long-lasting and serious impacts for the patients who are affected.

Clinical Approach to CRSD

Many patients with sleep problems complain of daytime sleepiness, fatigue, or other symptoms consistent with insomnia. These symptoms are also common in a variety of other medical and psychiatric disorders. Therefore, a systematic approach to determining the cause of the excessive daytime sleepiness or the sleep disruption is needed. Kales et al. suggested six important principles when taking a sleep-wake history: 1) define the specific sleep problem; 2) assess the clinical course; 3) differentiate between various sleep disorders; 4) evaluate sleep/wakefulness patterns; 5) question the bed partner; and 6) evaluate the

impact of the disorder on the patient¹⁰⁹. These principles apply for all causes of daytime sleepiness or sleep disruption, not only CRSD. In their 2011 review, Salas and Gamaldo¹¹⁰ summarized a series of key questions to ask of patients when evaluating sleep disorders (see Table 2), and these are useful in evaluation patients for CRSD as well. In fact, it is important to rule out other conditions that can affect the sleep-wake cycle in ways that can mimic CRSDs. Those conditions include poor sleep hygiene, depressive mood, temporary physical or psychological changes, and even medication side effects.

Sleep History Assessment

Because CRSD are defined as a misalignment between the timing of sleep and the timing of circadian rhythms, an evaluation of the patient's sleep-wake pattern across days or weeks (rather than a “snapshot” on a single night) is an important first step in making an accurate diagnosis. Evaluating the sleep-wake pattern can be done using standardized questionnaires that query the patient about habitual time to bed, time to fall asleep (sleep latency), usual waking time, frequency and duration of nighttime awakening, napping (including frequency, duration, and timing), and regularity of sleep and waking time (see below). This retrospective evaluation should then be supplemented with a prospective sleep log (and in some cases actigraphy) to confirm the diagnosis, as recommended by the American Academy of Sleep Medicine¹¹¹. In general, a polysomnogram is not necessary for CRSD diagnosis unless there is a suspicion of another sleep disorder as the cause of sleep disruption and/or daytime sleepiness¹¹¹.

In addition to the sleep-wake pattern, information about other factors that may influence sleep is an important part of the sleep history. Co-morbid conditions such as psychiatric disorders can make the diagnostic approach to symptoms of excessive daytime sleepiness or nighttime sleep disruption difficult. Medications for psychiatric diseases often have nighttime sleep or daytime sleepiness side effects. Most tricyclic antidepressants (TCAs), selective serotonin receptor inhibitors (SSRIs), and some monoamine oxidase inhibitors (MAOIs) show sedative side effects¹¹². Some studies suggest that there is a higher prevalence of CRSD in patients who have psychiatric problems like schizophrenia, but antipsychotic use in these patients may confound this observation because of the well-known sleep impacts of both first generation and second generation antipsychotics^{113, 114}.

Medications (not only psychiatric medications) with sleep disrupting and/or daytime drowsiness side effects can alter the sleep-wake homeostatic process, thus leading to problems sleeping at the desired time. Excessive stimulant use (including caffeine) and using stimulants too close to bedtime can make it difficult to fall asleep and delay normal sleep onset. In addition, many individuals with sleep difficulties will use over-the-counter remedies, herbal supplements, or alcohol to help them sleep. Thus, a thorough evaluation of all of the substances the patient is using, with attention to the time of day at which they are used, is important for evaluating the cause of the sleep difficulty and/or daytime sleepiness.

Evaluation of other behaviors that may influence sleep or daytime sleepiness is also a key component of the CRSD diagnostic process. Timing of exercise, typical evening activities, recent travel across time zones, work schedules, etc. should all be included in the patient history.

The impact of the sleep concern on the patient's well-being and daytime functioning is an important part of evaluating the patient for CRSD. There are several standard questionnaires that may be helpful in evaluating these impacts on the patient (see below).

Finally, evaluation of the timing of circadian rhythms in patients with suspected CRSD, while not currently supported by the American Academy of Sleep Medicine for CRSD evaluation other than Free-Running Type ¹¹¹, can not only help to confirm the diagnosis, it can provide important insight into the underlying mechanism causing the CRSD, and/or can help to optimize treatment timing ¹¹⁵⁻¹¹⁸.

Questionnaires

There are several questionnaires that can be useful in evaluating patients with possible CRSD. The Morningness-Eveningness Questionnaire (MEQ) ¹¹⁹ is a questionnaire designed by Horne and Östberg to rate an individual's propensity for morning or evening activity. It consists of 19 questions asking the patient about preferred timing of various daily activities, and scores can range from 16-86. The score places the individual into one of five morningness-eveningness categories, "definitely evening type", "moderately evening type", "neither type", "moderately morning type", and "definitely morning type". More recently, Roenneberg and colleagues have developed the Munich Chronotype Questionnaire (MCTQ) to assess the individual's relative morningness or eveningness, and actual sleep timing on weekdays and weekends ¹²⁰. Mid-sleep time on free days (days without school or work obligations) is considered to represent the individual's relative type. A major difference between the MEQ and the MCTQ is that the MEQ asks about preferred times of daily activities (including sleep and wake), while the MCTQ asks about actual sleep and wake timing.

There are also questionnaires that can be used to determine the degree of sleep problem or complaint experienced by the patient, as well as the degree of waking dysfunction. While these questionnaires have been developed for use in general sleep disorders populations, they may be of use to determine the extent of the problem experienced by the patient, and/or to re-assess the patient after initiating treatment to determine treatment efficacy. The Pittsburgh Sleep Quality Index (PSQI) consists of 19 questions about the patient's sleep over the past month ¹²¹. Four ask for specific information about bedtime, wake time, sleep latency, and sleep duration. The remaining questions ask the patient to rate on a 4-point scale how often they have experienced specific problems with their sleep, taken medications for sleep, experienced daytime sleepiness, etc. Of particular usefulness for evaluating patients with potential CRSD are questions about prolonged sleep latency and waking up too early. Responses are used to calculate seven component scores, and these are tallied for a global score, and the patient can then be placed into a category that indicates the severity of his/her sleep disruption. The Insomnia Severity Index (ISI) is a brief questionnaire containing seven questions. The patient is asked to rate aspects of his/her sleep on 5-point scales, with questions about the severity of sleep problems in the past two weeks and impact on waking functioning and other aspects of their life. Of particular usefulness in evaluating patients with possible CRSD, the initial question focuses on the severity of problems with

falling asleep, staying asleep, or waking too early. The overall ISI score can be used to place the patient into an insomnia severity category.

The Functional Outcomes of Sleep Questionnaire (FOSQ) consists of 35 questions about the difficulty level experienced by the patient when performing various daily activities within four domains of waking function¹²². Each question is rated on a 4-point scale, and there are sub-scale scores (within the four domains of waking function) as well as a global score designed to indicate the impact of excessive sleepiness on activities of daily living. The Epworth Sleepiness Scale (ESS) asks the patient about their likelihood of dozing or falling asleep in eight different situations, with four possible choices ranging from never to a high chance of dozing¹²³. A total score is then compiled and the patient placed into a daytime sleepiness category ranging from low, moderate, to high daytime sleepiness.

Treatments for Circadian Rhythm Sleep Disorders

There are several treatment modalities specifically for CRSD that are designed to address the underlying mismatch between the desired timing of sleep and the ability to fall asleep and remain asleep that characterizes CRSD, including chronotherapy, phototherapy, and melatonin administration. In addition to these CRSD-specific treatments, other treatments used for typical sleep initiation or sleep maintenance insomnias such as hypnotic medications or cognitive behavioral therapy (CBT), and treatments for excessive daytime sleepiness such as stimulants, can be used in CRSD. A detailed description of the evidence in support of each of the treatments for each CRSD type, and current practice parameters, is reviewed in a recent American Academy of Sleep Medicine Task Force report^{111, 126, 127}.

Chronotherapy

Chronotherapy involves modifying the scheduling of sleep to resynchronizing the underlying circadian rhythm so that it is at a normally entrained clock time¹²⁸. Chronotherapy attempts to gradually adjust the timing of the biological clock by delaying (for DSPS) or advancing (for ASPS) sleep and light-dark exposure times. This method works with the patient's underlying tendency for later (or earlier) bedtimes, and avoids abrupt changes in sleep times that can result in sleep deprivation. There are not many large trials of chronotherapy vs. other treatments, and there is one case report of a DSPS patient in whom chronotherapy resulted not in treatment but in Free-Running Disorder¹²⁹. In spite of these limitations, there are numerous small reports of successful chronotherapy, and it is typically well-tolerated by patients^{45, 128, 130}. In Free-Running Type and Irregular Sleep-Wake Type, there are few reports of the success of chronotherapy.

Timed Light Exposure (Phototherapy)

As described above, light is the most effective environmental cue for circadian entrainment, and the time of day at which light is received determines the amount and direction of circadian rhythm adjustment in response to that light exposure. Phototherapy takes an advantage of this by timing bright light exposure at strategic times designed to advance (in the case of DSPS) or delay (in the case of ASPS) the circadian system to a time that will allow sleep to occur at the desired time. In DSPS, morning exposure to bright light is used to

advance circadian rhythmicity and sleep time while in ASPS, conversely, evening exposure to bright light is used to delay circadian rhythmicity and sleep time. Typically, a commercially-available light box is used to deliver the light, which is brighter than standard indoor light sources (typically up to 2,500 lux). The patient is instructed to sit in front of the light box for 1 hour or more each morning (for DSPS) after arising at their desired wake time (or in evening prior to their desired bed time for ASPS). Studies of both sleep timing and the timing of biological rhythms have demonstrated that phototherapy can be effective for both DSPS and ASPS ^{111, 131-135}. There are also case reports showing that morning phototherapy can produce successful entrainment in patients with Free-Running Type ¹³⁶⁻¹³⁸. Unfortunately, compliance is an issue with phototherapy for many patients. The initial beneficial effects can take several days to occur during which time the patient often experiences sleep deprivation, and maintenance therapy is typically required once the desired sleep timing is achieved.

Enhancing the overall light-dark cycle (by limiting exposure to light at night and by enhancing the brightness of light exposure during the day) has been shown to improve the sleep-wake fragmentation of older institutionalized patients with Irregular Sleep-Wake Type ¹³⁹. Phototherapy has also been demonstrated to be beneficial as a pre-treatment for jet lag, although it may not be practical for the occasional traveler. There is evidence that phototherapy can aid in the adjustment of shift workers to night shifts or to a change in work schedule, although in such cases the phototherapy is typically delivered during the work hours and thus may not be practical in all work settings ^{111, 140-149}. In addition, the adjustment process takes several days, and thus for workers who rotate shifts on a weekly basis phototherapy alone will be insufficient to alleviate their shift work disorder. In the case of permanent night workers, they often adapt a night-sleep, day-wake schedule on weekends or days off for family and social reasons, and thus most never fully adapt to the night work schedule ^{150, 151}, and may not even wish to be fully adjusted to their night work schedule. For these reasons, partial adjustment via a “compromise” phase position has been advocated, as it improves sleep and on-shift alertness during night work but allows adoption of a more conventional schedule on days off ¹⁵²⁻¹⁵⁵. Alternatives to bright light boxes to achieve the goals of phototherapy for shift workers, including reducing light exposure in the morning using dark glasses, increasing light exposure in the afternoon or evening at home using natural or artificial light, and combinations of these, have also been tested.

Timed Melatonin Administration

The hormone melatonin is produced by the pineal gland at night, and its secretion is closely regulated by the circadian timing system. Exogenous melatonin has been shown to have both soporific (especially when administered during the biological daytime when endogenous melatonin is not present) and chronobiotic effects ¹⁵⁶⁻¹⁶². Melatonin administration in the evening has been shown to benefit patients with DSPS by producing advances of circadian rhythms and sleep timing ^{161, 163-166}. Doses of 0.5-5 mg are administered in the late afternoon or evening (1-6 hours before desired bedtime) for days or weeks, but the optimal dose and administration schedule have not been standardized ¹¹¹. There are also case reports that melatonin can be used to entrain sighted patients with Free-Running Type ^{136, 167, 168}, and melatonin has been used to successfully treat free-running

blind patients¹⁶⁹⁻¹⁷³. There is also evidence for melatonin's use in Jet Lag Type^{111, 174-178}, although not all studies have found that melatonin improves Jet Lag compared with placebo. This is likely due to the phase-dependent effects of melatonin, and if administered at the incorrect time melatonin may be ineffective or even produce the opposite effect to the desired one^{162, 179, 180}. Melatonin has also been used to treat patients with Shift Work Type, often in combination with phototherapy^{141, 142, 177, 181}.

Summary and Case Reports

In this brief review, the CRSD, which result from a mismatch between the desired timing of sleep and the circadian rhythm in sleep-wake propensity, are described. The features of the major CRSD, a diagnostic approach for evaluating patients suspected of having a CRSD, and typical treatments for CRSD are outlined. While most CRSD affect very few individuals, as alluded to above it can be difficult to differentiate between a primary CRSD and other sleep-related disorders. Furthermore, poor sleep hygiene can perpetuate or exacerbate a CRSD and make it challenging to treat. While there are several treatments for CRSD, optimal timing of the treatment with respect to the patient's underlying circadian rhythm is critical to a successful outcome, and can present the clinician with significant challenges.

To illustrate the approach to evaluating patients with possible CRSD, we close with presentation of two cases.

Case 1. A 24-year-old man with difficulty initiating sleep

Initial Presentation and Evaluation—Chief complaints: Sleep initiation difficulty, drowsiness in the morning, daytime fatigue. His Epworth Sleepiness Scale score was 10, indicating a moderate level of daytime sleepiness.

1) Sleep /Social History: The patient's usual time into bed is 1:00 am, with a sleep latency of 1 to 2 hours. His usual wake up time is 10 am.

The patient used to have a late sleep and wake typical of DSPS. This was not associated with sleep initiation difficulty (as long as he did not attempt to go to bed early), and he did not experience daytime fatigue. Several months ago, he began trying to wake up much earlier than his habitual wake time (around 5:00 am) in order to go to church, and had been afraid of waking up late. This led to increasing anxiety, and he began to have difficulty falling asleep and staying asleep.

Three years ago, he had depressive symptoms, which made him unable to go to school sometimes. However, he reports not having treatment for the depressive symptoms, which gradually improved after about one year.

2) Medications: None.

3) Other Medical, Psychiatric Conditions: None. No current depressive symptoms. The patient was given the Beck Depression Inventory, and his score was 8.

4) Initial Testing: The patient was asked to keep a sleep diary, which confirmed his late sleep and wake times. The patient was then evaluated with PSG and an evening salivary melatonin profile. His dim light melatonin onset occurred at 00:04 am, significantly later than normal. His night of PSG began at 02:30 am and showed a sleep latency of 8.1 minutes, a lower than usual amount of REM sleep (11%), some snoring but no evidence for sleep apnea (AHI 0), and a final wake time of 08:34 am, but was otherwise not remarkable.

5) Initial Diagnosis and Treatment Plan: The patient met all the clinical requirements to diagnose DSPS by ICSD-2 criteria: A). a delay of the major sleep episode relative to the desired sleep and wake time, as evidenced by a chronic or recurrent complaint of inability to fall asleep at a desired conventional clock time together with the inability to awaken at a desired and socially acceptable time; B). when allowed to choose their preferred schedule, patients will exhibit normal sleep quality and duration for age and maintain a delayed but stable phase of entrainment to the 24-hour sleep-wake pattern; C). sleep- log or actigraphy monitoring (including sleep diary) for at least seven days demonstrates a stable delay in the timing of the habitual sleep period. A delay in the timing of other circadian rhythms, such as the nadir of the core body temperature rhythm or DLMO, is useful for confirmation of the delayed phase. D). The sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. However, in addition to (and because of) the DSPS, the patient had developed anxiety about his ability to fall sleep, obtain sufficient sleep, and wake at the desired time, and so a treatment plan that addressed both issues was indicated.

Morning light therapy was initiated to address his DSPS. The patient was given a light therapy box and instructed to begin a 1-hour light exposure each morning at 08:30 am, and was asked to maintain a daily sleep log. Cognitive behavioral therapy (CBT) for the patient's sleep-related anxiety was also initiated. This included group therapy sessions and sleep restriction.

6) Follow-Up: The patient visited the clinic on a weekly basis to monitor his progress. His sleep logs showed sleep between 02:00 and 09:30 am. The patient attended five group therapy sessions as part of his CBT. His sleep quality improved and his sleep latency became shorter after sleep restriction. His sleep-related anxiety also diminished. At a 7-week follow up visit, his sleep latency was reduced to 30 minutes or less, and his usual wake up time was 7:50 am.

Case 2. A 67-year-old woman with a complaint of early awakening, early sleep onset, and excessive daytime sleepiness

Initial Presentation and Evaluation—Chief complaints: Sleep maintenance difficulty, daytime fatigue.

1) Sleep /Social History: The patient is a 67-year old woman. She reports going to bed and waking earlier than desired on a daily basis for at least the past year. This has caused her to have extreme daytime sleepiness, requiring her to nap each day. She states that “often feel as if I have not had enough sleep”.

The patient reports going to bed around 9 or 10 pm and waking around 4:30 am. This is about 1.5 hours earlier than her desired wake time of 6 am. She reports a sleep latency of 5-20 minutes, and waking once every night to void. Approximately once per week, she wakes around 2 am, thinks about work, gets up to do work until she is sleepy again (usually after about two hours), and then returns to sleep for a few hours, sometimes sleeping as late as 9 am. Her Pittsburgh Sleep Quality Index score is 11, indicating moderate sleep difficulty.

She reports feeling so sleepy during the daytime that she takes an afternoon nap each day, with the nap lasting from 15 minutes to 2 hours. Her Epworth Sleepiness Scale score is 18, indicating severe daytime sleepiness.

The patient reports not snoring, and her BMI is 21.9. Her normal BMI and report of not snoring make it less likely that a cause of her nighttime awakenings and extreme daytime sleepiness is sleep apnea, even though her age and post-menopausal status make her more likely than a younger woman to suffer from this common sleep disorder¹⁸². However, from the information we have sleep apnea cannot be ruled out as a possible cause of her sleep disruption and excessive daytime sleepiness, given that even normal weight patients and those who do not report snoring may have sleep disordered breathing^{183, 184}. She does not report symptoms of Restless Legs Syndrome, and does not report limb movements during the night. Thus, Periodic Limb Movement Disorder or other sleep-related movement disorders are an unlikely cause of her daytime sleepiness. She has not traveled across time zones for more than a year, and does not have a history of night or rotating shift work, both of which could cause a circadian rhythm sleep disorder. She reports drinking 1 cup of decaffeinated coffee daily, an occasional cup of tea, but otherwise no drinks or foods that contain caffeine. She is a non-smoker and drinks 3-4 glasses of wine per week. Her modest use of caffeine, nicotine, and alcohol are unlikely to be the source of her sleep difficulty.

2) Medications: Amlodipine (a calcium channel blocker; 2.5mg daily at bedtime) for the past six months. Alendronate (a bisphosphonate; 70mg weekly) for the past three months. Transdermal estradiol about two times per week for the past four years. A multivitamin, evening primrose, a bone formula supplement, and 2,000mg of vitamin D each day. Ibuprofen or aspirin occasionally for pain. She denies taking any other supplements or medications. Evaluation of the reported side effects of her medications on sleep or daytime sleepiness reveals only that her calcium channel blocker lists drowsiness and tired feeling as a side effect. However, the patient takes this medication at bedtime, so it this and her other medications are unlikely to be the cause of her sleep disruption or daytime sleepiness.

3) Other Medical, Psychiatric Conditions: She reports no history of depression or other psychiatric disorder, and her score on the Beck Depression Inventory was 2, a normal (non-depressed) score. She has well-controlled hypertension [BP 115/73].

The patient had arthroscopic knee surgery five years ago, but reports no ongoing pain associated with this that might disrupt her sleep. She suffered a concussion without loss of consciousness six months ago. She reports that her sleep did not change after the concussion.

4) Initial Impression and Testing: The patient does meet some of the diagnostic criteria for ASPS as outlined in the ICSD-2. These include an advance in the timing of the major sleep period related to desired sleep timing. However, the patient's reported sleep patterns (middle-of-the-night waking on some nights and then return to sleep; wake times varying by several hours; daytime napping of varying durations) make it difficult to evaluate whether the patient's sleep hygiene behaviors may be contributing to subsequent sleep disruption. The patient's history of concussion may be important, but she reports that the sleep problem began before and did not change as a result of the concussion.

The patient was asked to maintain a sleep-wake log for 1-2 weeks, and to document the use and timing of medications, caffeinated drinks, and alcohol, as well as the timing and duration of naps.

5) Initial Follow-up: The patient maintained a detailed sleep log for nine days. During that time, her time into bed varied by nearly two hours (from 9:01 to 10:56 pm), and her final wake time varied by more than an hour (from 4:22 to 5:38 am). Her self-reported sleep latencies were quite short, being less than five minutes on all but one of the nights (when it was 15 minutes). On six of the nights, she woke one or two times during the night, and on five of the nights it was for less than five minutes each time, which is not unusual for someone of her age and is unlikely to be the cause of her daytime sleepiness. On one of the nights she was awake for 30 minutes during the night. Considering her reported bed and wake times, sleep latencies, and nighttime awakenings, her sleep durations ranged from 4.67 to 8.25 hours, and were longer than seven hours on seven of the nine nights. She reported napping on only one of the days, but that nap was four hours long. The day with the long nap preceded the night with the shortest sleep duration.

6) Diagnosis and Treatment Plan: Similar to clinical requirements to diagnose DSPS above, the ICSD-2 criteria for ASPS are: A). an advance of the major sleep episode relative to the desired sleep and wake time, as evidenced by a chronic or recurrent complaint of inability to stay awake until the desired conventional clock time together with the inability to remain asleep until a desired and socially acceptable time; B). when allowed to choose their preferred schedule, patients will exhibit normal sleep quality and duration for age and maintain an advanced but stable phase of entrainment to the 24-hour sleep-wake pattern; C). sleep- log or actigraphy monitoring (including sleep diary) for at least seven days demonstrates a stable advance in the timing of the habitual sleep period. An advance in the timing of other circadian rhythms, such as the nadir of the core body temperature rhythm or DLMO, is useful for confirmation of the advanced phase. D). The sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder.

While the patient meets ASPS criteria A-C, her poor sleep hygiene (very irregular sleep times from night-to-night and daytime napping) is likely contributing to her ongoing sleep difficulty at night, and when this leads her to nights of very short sleep, it may in turn lead to her daytime sleepiness. Thus, a treatment plan to address both her ASPS and her sleep hygiene was indicated.

The patient was counseled about her sleep hygiene, with particular attention to the duration of daytime naps (keeping them to less than 30 minutes), more consistent bedtimes and wake times (getting in to bed and arising at nearly the same time each day, regardless of her sleep quality), and remaining in bed in darkness attempting to return to sleep when she wakes in the middle of the night rather than getting up to do work. In addition, the patient was started on a regimen of evening phototherapy. She was given a light box and instructed to use it for 1-2 hours each evening beginning at 8:00 pm, and was asked to keep a sleep log.

6) Follow-Up: The patient visited the clinic four weeks later to monitor her progress. Her sleep logs showed sleep between 9:30-10:00 pm and rise time on most mornings between 05:00 and 06:00 am. She still felt the need to have daytime naps, but on most days these were limited to less than half an hour. If her daytime sleepiness persists, further follow-up may include an at-home or laboratory sleep evaluation to rule out sleep apnea or periodic limb movements.

Acknowledgments

Dr. Kim is supported by Howard OsanDongtan Hospital. Dr. Lee is supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (2010-0003160 to JHL). Dr. Duffy is supported by research grants from the US National Institutes of Health [R01 AG044416, P01 AG09975, R01 HL093279; R01 HL094654] and the Brigham and Women's Hospital BRI Fund to Sustain Research Excellence.

References

1. Yazaki M, Shirakawa S, Okawa M, Takahashi K. Demography of sleep disturbances associated with circadian rhythm disorders in Japan. *Psychiatry Clin Neurosci*. 1999; 53:267–68. [PubMed: 10459707]
2. Schrader H, Bovim G, Sand T. The prevalence of delayed and advanced sleep phase syndromes. *J Sleep Res*. 1993; 2:51–55. [PubMed: 10607071]
3. Ando K, Kripke DF, Ancoli-Israel S. Delayed and advanced sleep phase symptoms. *Isr J Psychiatry Relat Sci*. 2002; 39:11–8. [PubMed: 12013705]
4. Crowley SJ, Acebo C, Carskadon MA. Sleep, circadian rhythms, and delayed phase in adolescence. *Sleep Med*. 2007; 8(6):602–12. [PubMed: 17383934]
5. Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. *Sleep Med*. 2007; 8(6): 566–77. [PubMed: 17395535]
6. Wyatt JK. Delayed sleep phase syndrome: Pathophysiology and treatment options. *Sleep*. 2004; 27(6):1195–203. [PubMed: 15532214]
7. Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. *Proc Natl Acad Sci USA*. 1972; 69(6):1583–86. [PubMed: 4556464]
8. Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. *Brain Res*. 1972; 42:201–06. [PubMed: 5047187]
9. Moore RY. Retinohypothalamic projection in mammals: A comparative study. *Brain Res*. 1973; 49:403–09. [PubMed: 4124397]
10. Menaker M, Takahashi JS, Eskin A. The physiology of circadian pacemakers. *Annu Rev Physiol*. 1978; 40:501–26. [PubMed: 345954]
11. Inouye ST, Kawamura H. Persistence of circadian rhythmicity in a mammalian hypothalamic “island” containing the suprachiasmatic nucleus. *Proc Natl Acad Sci USA*. 1979; 76:5962–66. [PubMed: 293695]
12. Schwartz WJ, Gross RA, Morton MT. The suprachiasmatic nuclei contain a tetrodotoxin-resistant circadian pacemaker. *Proc Natl Acad Sci USA*. 1987; 84:1694–98. [PubMed: 3470750]

13. Klein, DC.; Moore, RY.; Reppert, SM. Suprachiasmatic nucleus: The mind's clock. New York: Oxford University Press; 1991.
14. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. *Science*. 1999; 284:2177–81. [PubMed: 10381883]
15. Duffy JF, Cain SW, Chang AM, et al. Sex difference in the near-24-hour intrinsic period of the human circadian timing system. *Proc Nat Acad Sci USA*. 2011; 108:15602–08. [PubMed: 21536890]
16. Middleton B, Arendt J, Stone BM. Human circadian rhythms in constant dim light (8 lux) with knowledge of clock time. *J Sleep Res*. 1996; 5:69–76. [PubMed: 8795806]
17. Hiddinga AE, Beersma DGM, van den Hoofdakker RH. Endogenous and exogenous components in the circadian variation of core body temperature in humans. *J Sleep Res*. 1997; 6:156–63. [PubMed: 9358393]
18. Waterhouse J, Minors D, Folkard S, et al. Light of domestic intensity produces phase shifts of the circadian oscillator in humans. *Neurosci Lett*. 1998; 245:97–100. [PubMed: 9605494]
19. Carskadon MA, Labyak SE, Acebo C, Seifer R. Intrinsic circadian period of adolescent humans measured in conditions of forced desynchrony. *Neurosci Lett*. 1999; 260:129–32. [PubMed: 10025716]
20. Kelly TL, Neri DF, Grill JT, et al. Nonentrained circadian rhythms of melatonin in submariners scheduled to an 18-hour day. *J Biol Rhythms*. 1999; 14:190–96. [PubMed: 10452330]
21. Honma K, Honma S. A human phase response curve for bright light pulses. *Jpn J Psychiatry Neurol*. 1988; 42:167–68.
22. Czeisler CA, Kronauer RE, Allan JS, et al. Bright light induction of strong (type 0) resetting of the human circadian pacemaker. *Science*. 1989; 244:1328–33. [PubMed: 2734611]
23. Minors DS, Waterhouse JM, Wirz-Justice A. A human phase-response curve to light. *Neurosci Lett*. 1991; 133:36–40. [PubMed: 1791996]
24. Khalsa SBS, Jewett ME, Cajochen C, Czeisler CA. A phase response curve to single bright light pulses in human subjects. *Journal of Physiology (Lond)*. 2003; 549:945–52. [PubMed: 12717008]
25. St Hilaire MA, Gooley JJ, Khalsa SB, Kronauer RE, Czeisler CA, Lockley SW. Human phase response curve to a 1 h pulse of bright white light. *J Physiol*. 2012; 590:3035–45. [PubMed: 22547633]
26. Dawson D, Lack L, Morris M. Phase resetting of the human circadian pacemaker with use of a single pulse of bright light. *Chronobiol Int*. 1993; 10:94–102. [PubMed: 8500194]
27. Strogatz SH, Kronauer RE, Czeisler CA. Circadian pacemaker interferes with sleep onset at specific times each day: Role in insomnia. *Am J Physiol*. 1987; 253:R172–R78. [PubMed: 3605382]
28. Czeisler CA, Weitzman ED, Moore-Ede MC, Zimmerman JC, Knauer RS. Human sleep: Its duration and organization depend on its circadian phase. *Science*. 1980; 210:1264–67. [PubMed: 7434029]
29. Dijk DJ, Czeisler CA. Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. *Neurosci Lett*. 1994; 166:63–68. [PubMed: 8190360]
30. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. *J Neurosci*. 1995; 15:3526–38. [PubMed: 7751928]
31. Borbély AA. A two process model of sleep regulation. *Human Neurobiology*. 1982; 1:195–204. [PubMed: 7185792]
32. Münch MY, Cain SW, Duffy JF. Biological Rhythms Workshop IC: Sleep and Rhythms. *Cold Spring Harb Symp Quant Biol*. 2007; 72:35–46. [PubMed: 18419261]
33. The International Classification of Sleep Disorders; Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine; 2005.
34. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: Incidence and clinical significance. *J Clin Endocrinol Metab*. 1992; 75:127–34. [PubMed: 1619000]

35. Klein T, Martens H, Dijk DJ, Kronauer RE, Seely EW, Czeisler CA. Chronic non-24-hour circadian rhythm sleep disorder in a blind man with a regular 24-hour sleep-wake schedule. *Sleep*. 1993; 16:333–43. [PubMed: 8341894]
36. Klerman EB, Rimmer DW, Dijk DJ, Kronauer RE, Rizzo JF III, Czeisler CA. Nonphotic entrainment of the human circadian pacemaker. *Am J Physiol*. 1998; 274:R991–R96. [PubMed: 9575961]
37. Emens JS, Lewy AJ, Lefler BJ, Sack RL. Relative coordination to unknown “Weak Zeitgebers” in free-running blind individuals. *J Biol Rhythms*. 2005; 20:159–67. [PubMed: 15834112]
38. Wright KP Jr, Gronfier C, Duffy JF, Czeisler CA. Intrinsic period and light intensity determine the phase relationship between melatonin and sleep in humans. *J Biol Rhythms*. 2005; 20:168–77. [PubMed: 15834113]
39. Gronfier C, Wright KP Jr, Kronauer RE, Czeisler CA. Entrainment of the human circadian pacemaker to longer-than-24-h days. *Proc Natl Acad Sci USA*. 2007; 104:9081–86. [PubMed: 17502598]
40. Klerman EB, Dijk DJ, Kronauer RE, Czeisler CA. Simulations of light effects on the human circadian pacemaker: Implications for assessment of intrinsic period. *Am J Physiol*. 1996; 270:R271–R82. [PubMed: 8769811]
41. Gooley JJ, Chamberlain K, Smith KA, et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. *J Clin Endocrinol Metab*. 2011; 96:E463–E72. [PubMed: 21193540]
42. Chang A, Aeschbach D, Duffy JF, Czeisler CA. Impact of evening use of light-emitting electronic readers on circadian timing and sleep latency. *Sleep*. 2012; 35:A206.
43. Burgess HJ, Eastman CI. The dim light melatonin onset following fixed and free sleep schedules. *J Sleep Res*. 2005; 14:229–37. [PubMed: 16120097]
44. Dagan Y, Eisenstein M. Circadian rhythm sleep disorders: Toward a more precise definition and diagnosis. *Chronobiol Int*. 1999; 16:213–22. [PubMed: 10219492]
45. Ito A, Ando K, Hayakawa T, et al. Long-term course of adult patients with delayed sleep phase syndrome. *Jpn J Psychiatry Neurol*. 1993; 47:563–67. [PubMed: 8301870]
46. Carrier J, Monk TH, Buysse DJ, Kupfer DJ. Sleep and morningness-eveningness in the ‘middle’ years of life (20–59y). *J Sleep Res*. 1997; 6:230–37. [PubMed: 9493522]
47. Kitamura S, Hida A, Enomoto M, et al. Intrinsic circadian period of sighted patients with circadian rhythm sleep disorder, free-running type. *Biol Psychiatry*. 2013; 73:63–9. [PubMed: 22846439]
48. Rogers HL, Reilly SM. A survey of the health experiences of international business travelers. Part One--Physiological aspects. *AAOHN J*. 2002; 50:449–59. [PubMed: 12400229]
49. Gander PH, Gregory KB, Miller DL, Graeber RC, Connell LJ, Rosekind MR. Flight crew fatigue V: Long-haul air transport operations. *Aviat Space Environ Med*. 1998; 69:B37–B48. [PubMed: 9749939]
50. Winget CM, DeRoshia CW, Markley CL, Holley DC. A review of human physiological and performance changes associated with desynchronization of biological rhythms. *Aviat Space Environ Med*. 1984; 55:1085–96. [PubMed: 6151390]
51. Pukkala E, Helminen M, Haldorsen T, et al. Cancer incidence among Nordic airline cabin crew. *Int J Cancer*. 2012; 131:2886–97. [PubMed: 22447246]
52. Kim JN, Lee BM. Risk factors, health risks, and risk management for aircraft personnel and frequent flyers. *J Toxicol Environ Health B Crit Rev*. 2007; 10(3):223–34. [PubMed: 17454553]
53. United States Department of Labor Bureau of Labor Statistics. Workers on Flexible and Shift Schedules in May 2004. Washington, D.C.: U.S. Department of Labor; 2005.
54. United States Department of Labor Bureau of Labor Statistics. Table 4 Shift usually worked: Full-time wage and salary workers by selected characteristics. Washington, D.C.: U.S. Department of Labor; 2005.
55. United States Department of Labor Bureau of Labor Statistics. The employment situation - August 2012. Washington, D.C.: U.S. Department of Labor; 2012.
56. Smith MJ, Colligan MJ, Tasto DL. Health and safety consequences of shift work in the food processing industry. *Ergonomics*. 1982; 25:133–44. [PubMed: 7200870]

57. Smith L, Folkard S, Poole CJM. Increased injuries on night shift. *Lancet*. 1994; 344:1137–39. [PubMed: 7934499]
58. Åkerstedt T, Fredlund P, Gillberg M, Jansson B. A prospective study of fatal occupational accidents-relationship to sleeping difficulties and occupational factors. *J Sleep Res*. 2002; 11:69–71. [PubMed: 11869429]
59. Gold DR, Rogacz S, Bock N, et al. Rotating shift work, sleep, and accidents related to sleepiness in hospital nurses. *Am J Public Health*. 1992; 82:1011–14. [PubMed: 1609900]
60. Mitler MM, Carskadon MA, Czeisler CA, Dement WC, Dinges DF, Graeber RC. Catastrophes, sleep, and public policy: Consensus report. *Sleep*. 1988; 11:100–09. [PubMed: 3283909]
61. Folkard S. Shift work, safety, and aging. *Chronobiol Int*. 2008; 25:183–98. [PubMed: 18484360]
62. Rogers E, Wiatrowski WJ. Injuries, illnesses, and fatalities among older workers. *Monthly Labor Review*. Oct.2005 :24–30. 2005.
63. Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work sleep disorder: Prevalence and consequences beyond that of symptomatic day workers. *Sleep*. 2004; 27:1453–62. [PubMed: 15683134]
64. Novak RD, Auvil-Novak SE. Focus group evaluation of night nurse shiftwork difficulties and coping strategies. *Chronobiol Int*. 1996; 13:457–63. [PubMed: 8974191]
65. Safety Study: Fatigue, Alcohol, Other Drugs, and Medical Factors in Fatal-to-the-Driver Heavy Truck Crashes (Volume 1). Washington DC: National Transportation Safety Board; 1990.
66. Harris, W. Fatigue, circadian rhythm, and truck accidents. In: Mackie, R., editor. *Vigilance Theory, Operational Performance, and Physiological Correlates*. New York: Plenum; 1977. p. 133-46.
67. Pack AI, Pack AM, Rodgman E, Cucchiara A, Dinges DF, Schwab CW. Characteristics of crashes attributed to the driver having fallen asleep. *Accid Anal Prev*. 1995; 27:769–75. [PubMed: 8749280]
68. Langlois PH, Smolensky MH, Hsi BP, Weir FW. Temporal patterns of reported single-vehicle car and truck accidents in Texas, USA during 1980-1983. *Chronobiol Int*. 1985; 2:131–40. [PubMed: 3870843]
69. Horne JA, Reyner LA. Sleep related vehicle accidents. *Brit Med J*. 1995; 310:565–67. [PubMed: 7888930]
70. Boufous S, Williamson A. Work-related traffic crashes: A record linkage study. *Accid Anal Prev*. 2006; 38:14–21. [PubMed: 16043107]
71. Lee ML, Howard ME, Horrey WJ, et al. Ocular measurement of drowsiness and driving impairment in shift-workers. *Sleep*. 2012; 35(Suppl):A68.
72. Ftouni S, Sletten TL, Howard M, et al. Objective and subjective measures of sleepiness, and their associations with on-road driving events in shift workers. *J Sleep Res*. 2013; 22:58–69. [PubMed: 22861524]
73. Knutsson A, Hallquist J, Reuterwall C, Theorell T, Åkerstedt T. Shiftwork and myocardial infarction: A case-control study. *Occup Environ Med*. 1999; 56:46–50. [PubMed: 10341746]
74. Kawachi I, Colditz GA, Stampfer MJ, et al. Prospective study of shift work and risk of coronary heart disease in women. *Circulation*. 1995; 92:3178–82. [PubMed: 7586301]
75. Fujino Y, Iso H, Tamakoshi A, et al. A prospective cohort study of shift work and risk of ischemic heart disease in Japanese male workers. *Am J Epidemiol*. 2006; 164:128–35. [PubMed: 16707650]
76. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. *Proc Natl Acad Sci USA*. 2009; 106:4453–58. [PubMed: 19255424]
77. Brown DL, Feskanich D, Sanchez BN, Rexrode KM, Schernhammer ES, Lisabeth LD. Rotating night shift work and the risk of ischemic stroke. *Am J Epidemiol*. 2009; 169:1370–77. [PubMed: 19357324]
78. Vener KJ, Szabo S, Moore JG. The effect of shift work on gastrointestinal (GI) function: A review. *Chronobiologia*. 1989; 16:421–39. [PubMed: 2697524]

79. Fischer FM, Morata TC, Latorre Mdo R, et al. Effects of environmental and organizational factors on the health of shiftworkers of a printing company. *J Occup Environ Med.* 2001; 43:882–89. [PubMed: 11665457]
80. Lin YC, Hsiao TJ, Chen PC. Shift work aggravates metabolic syndrome development among early-middle-aged males with elevated ALT. *World J Gastroenterol.* 2009; 15:5654–61. [PubMed: 19960561]
81. Ha M, Park J. Shiftwork and metabolic risk factors of cardiovascular disease. *J Occup Health.* 2005; 47:89–95. [PubMed: 15824472]
82. De Bacquer D, Van Risseghem M, Clays E, Kittel F, De Backer G, Braeckman L. Rotating shift work and the metabolic syndrome: a prospective study. *Int J Epidemiol.* 2009; 38:848–54. [PubMed: 19129266]
83. Buxton OM, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. *Soc Sci Med.* 2010; 71:1027–36. [PubMed: 20621406]
84. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: A systematic review and meta-analysis. *Diabetes Care.* 2010; 33:414–20. [PubMed: 19910503]
85. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: A systematic review and meta-analysis of prospective studies. *Sleep.* 2010; 33:585–92. [PubMed: 20469800]
86. Toshihiro M, Saito K, Takikawa S, Takebe N, Onoda T, Satoh J. Psychosocial factors are independent risk factors for the development of Type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. *Diabet Med.* 2008; 25:1211–17. [PubMed: 19046200]
87. Pan A, Schernhammer ES, Sun Q, Hu FB. Rotating night shift work and risk of type 2 diabetes: Two prospective cohort studies in women. *PLoS Med.* 2011; 8:e1001141. [PubMed: 22162955]
88. Hansen J. Light at night, shiftwork, and breast cancer risk. *J Nat Cancer Inst.* 2001; 93:1513–15. [PubMed: 11604468]
89. Hansen J. Increased breast cancer risk among women who work predominantly at night. *Epidemiology.* 2001; 12:74–77. [PubMed: 11138824]
90. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. *J Natl Cancer Inst.* 2001; 93:1563–68. [PubMed: 11604480]
91. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. *Eur J Cancer.* 2005; 41:2023–32. [PubMed: 16084719]
92. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. *J Natl Cancer Inst.* 2003; 95:825–28. [PubMed: 12783938]
93. Sigurdardottir LG, Valdimarsdottir UA, Fall K, et al. Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies. *Cancer Epidemiol Biomarkers Prev.* 2012; 21:1002–11. [PubMed: 22564869]
94. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. *Cancer Res.* 2007; 67:10618–22. [PubMed: 17975006]
95. Kubo T, Ozasa K, Mikami K, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: Findings from the Japan collaborative cohort study. *Am J Epidemiol.* 2006; 164:549–55. [PubMed: 16829554]
96. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. *J Natl Cancer Inst.* 2001; 93:1557–62. [PubMed: 11604479]
97. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. *Eur Heart J.* 2011; 32:1484–92. [PubMed: 21300732]
98. Spiegel K, Leproult R, L'Hermite-Balériaux M, Copinschi G, Penev PD, Van Cauter E. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate

- regulation, cortisol, and thyrotropin. *J Clin Endocrinol Metab.* 2004; 89:5762–71. [PubMed: 15531540]
99. Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med.* 2004; 1:210–17.
 100. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. *Ann NY Acad Sci.* 2008; 1129:287–304. [PubMed: 18591489]
 101. Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. *Diabetes.* 2010; 59:2126–23. [PubMed: 20585000]
 102. Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. *Proc Natl Acad Sci USA.* 2008; 105:1044–49. [PubMed: 18172212]
 103. Bryant PA, Trinder J, Curtis N. Sick and tired: Does sleep have a vital role in the immune system? *Nat Rev Immunol.* 2004; 4:457–67. [PubMed: 15173834]
 104. Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. *Ann NY Acad Sci.* 2010; 1193:48–59. [PubMed: 20398008]
 105. van Leeuwen WM, Lehto M, Karisola P, et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. *PLoS One.* 2009; 4:e4589. [PubMed: 19240794]
 106. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. *J Am Coll Cardiol.* 2004; 43:678–83. [PubMed: 14975482]
 107. Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. *Sleep.* 2007; 30:1145–52. [PubMed: 17910386]
 108. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. *J Clin Endocrinol Metab.* 2004; 89:2119–26. [PubMed: 15126529]
 109. Kales A, Soldatos CR, Kales JD. Sleep disorders: Insomnia, sleepwalking, night terrors, nightmares, and enuresis. *Ann Intern Med.* 1987; 106:582–92. [PubMed: 3548525]
 110. Salas RE, Gamaldo CE. Diagnostic and therapeutic considerations in sleep disorders. *JCOM.* 2011; 18:129–44.
 111. Morgenthaler TI, Lee-Chiong T, Alessi C, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. *Sleep.* 2007; 30:1445–59. [PubMed: 18041479]
 112. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. *Hum Psychopharmacol.* 2005; 20:533–59. [PubMed: 16229049]
 113. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. *Br J Psychiatry.* 2012; 200:308–16. [PubMed: 22194182]
 114. Cohrs S. Sleep disturbances in patients with schizophrenia : Impact and effect of antipsychotics. *CNS Drugs.* 2008; 22:939–62. [PubMed: 18840034]
 115. Rahman SA, Kayumov L, Tchmoutina EA, Shapiro CM. Clinical efficacy of dim light melatonin onset testing in diagnosing delayed sleep phase syndrome. *Sleep Med.* 2009; 10:549–55. [PubMed: 18725185]
 116. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: A meta-analysis. *Sleep.* 2010; 33:1605–14. [PubMed: 21120122]
 117. Keijzer H, Smits MG, Peeters T, Looman CWN, Endenburg SC, Gunnewiek MTK. Evaluation of salivary melatonin measurements for Dim Light Melatonin Onset calculations in patients with possible sleep-wake rhythm disorders. *Clin Chim Acta.* 2011; 412:1616–20. [PubMed: 21601566]
 118. Keijzer H, Smits MG, Duffy JF, Curfs LMG. Why circadian timing should be measured before treatment of patients with sleep timing disorders. *Sleep Med Rev.* Submitted to.
 119. Horne JA, Östberg O. A self-assessment questionnaire to determine morningness- eveningness in human circadian rhythms. *Int J Chronobiol.* 1976; 4:97–110. [PubMed: 1027738]

120. Roenneberg T, Wirz-Justice A, Mellow M. Life between clocks: Daily temporal patterns of human chronotypes. *J Biol Rhythms*. 2003; 18:80–90. [PubMed: 12568247]
121. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. *Psychiatry Res*. 1989; 28:193–213. [PubMed: 2748771]
122. Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. *Sleep*. 1997; 20:835–43. [PubMed: 9415942]
123. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. *Sleep*. 1991; 14:540–45. [PubMed: 1798888]
124. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961; 4:561–71. [PubMed: 13688369]
125. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med*. 2001; 2:297–307. [PubMed: 11438246]
126. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: Part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. *Sleep*. 2007; 30:1460–83. [PubMed: 18041480]
127. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: Part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. *Sleep*. 2007; 30:1484–501. [PubMed: 18041481]
128. Czeisler CA, Richardson GS, Coleman RM, et al. Chronotherapy: Resetting the circadian clocks of patients with delayed sleep phase insomnia. *Sleep*. 1981; 4:1–21. [PubMed: 7232967]
129. Oren DA, Wehr TA. Hypernyctohemeral syndrome after chronotherapy for delayed sleep phase syndrome. *New Engl J Med*. 1992; 327:1762. [PubMed: 1435929]
130. Moldofsky H, Musisi S, Phillipson EA. Treatment of advanced sleep phase syndrome by phase advance chronotherapy. *Sleep Res*. 1985; 14:307–07.
131. Rosenthal NE, Joseph-Vanderpool JR, Levendosky AA, et al. Phase-shifting effects of bright morning light as treatment for delayed sleep phase syndrome. *Sleep*. 1990; 13:354–61. [PubMed: 2267478]
132. Watanabe T, Kato M, Sekimoto M, Kajimura N, Takahashi K. Polysomnography and body temperature changes by phototherapy in a delayed sleep phase syndrome case. *Psychiatry Clin Neurosci*. 1998; 52:255–56. [PubMed: 9628182]
133. Campbell SS, Dawson D, Anderson MW. Alleviation of sleep maintenance insomnia with timed exposure to bright light. *J Am Geriatr Soc*. 1993; 41:829–36. [PubMed: 8340561]
134. Lack L, Wright H. The effect of evening bright light in delaying the circadian rhythms and lengthening the sleep of early morning awakening insomniacs. *Sleep*. 1993; 16:436–43. [PubMed: 8378685]
135. Cole RJ, Smith JS, Alcala YC, Elliott JA, Kripke DF. Bright-light mask treatment of delayed sleep phase syndrome. *J Biol Rhythms*. 2002; 17:89–101. [PubMed: 11837952]
136. Hayakawa T, Kamei Y, Urata J, et al. Trials of bright light exposure and melatonin administration in a patient with non-24 hour sleep-wake syndrome. *Psychiatry Clin Neurosci*. 1998; 52:261–62. [PubMed: 9628185]
137. Watanabe T, Kajimura N, Kato M, Sekimoto M, Hori T, Takahashi K. Case of non-24 h sleep-wake syndrome patient improved by phototherapy. *Psychiatry Clin Neurosci*. 2000; 54:369–70. [PubMed: 11186118]
138. Hoban TM, Sack RL, Lewy AJ, Miller LS, Singer CM. Entrainment of a free-running human with bright light? *Chronobiol Int*. 1989; 6:347–53. [PubMed: 2627721]
139. Ancoli-Israel S, Gehrman P, Martin JL, et al. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. *Behav Sleep Med*. 2003; 1:22–36. [PubMed: 15600135]
140. Boivin DB, James FO. Circadian adaptation to night-shift work by judicious light and darkness exposure. *J Biol Rhythms*. 2002; 17:556–67. [PubMed: 12465889]
141. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. *Sleep Med Rev*. 2002; 6:407–20. [PubMed: 12531129]

142. Crowley SJ, Lee C, Tseng CY, Fogg LF, Eastman CI. Combinations of bright light, scheduled dark, sunglasses, and melatonin to facilitate circadian entrainment to night shift work. *J Biol Rhythms*. 2003; 18:513–23. [PubMed: 14667152]
143. Dawson D, Encel N, Lushington K. Improving adaptation to simulated night shift: Timed exposure to bright light versus daytime melatonin administration. *Sleep*. 1995; 18:11–21. [PubMed: 7761738]
144. Eastman CI, Boulos Z, Terman M, Campbell SS, Dijk DJ, Lewy AJ. Light treatment for sleep disorders: Consensus Report. VI. Shift Work. *J Biol Rhythms*. 1995; 10:157–64. [PubMed: 7632989]
145. Horowitz TS, Cade BE, Wolfe JM, Czeisler CA. Efficacy of bright light and sleep/darkness scheduling in alleviating circadian maladaptation to night work. *Am J Physiol Endocrinol Metab*. 2001; 281:E384–E91. [PubMed: 11440916]
146. James FO, Walker CD, Boivin DB. Controlled exposure to light and darkness realigns the salivary cortisol rhythm in night shift workers. *Chronobiol Int*. 2004; 21:961–72. [PubMed: 15646242]
147. Martin SK, Eastman CI. Medium-intensity light produces circadian rhythm adaptation to simulated night-shift work. *Sleep*. 1998; 21:154–65. [PubMed: 9542799]
148. Czeisler CA, Johnson MP, Duffy JF, Brown EN, Ronda JM, Kronauer RE. Exposure to bright light and darkness to treat physiologic maladaptation to night work. *New Engl J Med*. 1990; 322:1253–59. [PubMed: 2325721]
149. Santhi N, Duffy JF, Horowitz TS, Czeisler CA. Moderate intensity light in combination with scheduled sleep facilitates adaptation to night work. *Sleep*. 2006; 29:A52–A 53.
150. Folkard S. Do permanent night workers show circadian adjustment? A review based on the endogenous melatonin rhythm. *Chronobiol Int*. 2008; 25:215–24. [PubMed: 18533325]
151. Gumenyuk V, Roth T, Drake CL. Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorder. *Chronobiol Int*. 2012; 29:928–36. [PubMed: 22823876]
152. Chapdelaine S, Paquet J, Dumont M. Effects of partial circadian adjustments on sleep and vigilance quality during simulated night work. *J Sleep Res*. 2012; 21:380–89. [PubMed: 22329989]
153. Lee C, Smith MR, Eastman CI. A compromise phase position for permanent night shift workers: circadian phase after two night shifts with scheduled sleep and light/dark exposure. *Chronobiol Int*. 2006; 23:859–75. [PubMed: 16887753]
154. Smith MR, Eastman CI. Night shift performance is improved by a compromise circadian phase position: study 3. Circadian phase after 7 night shifts with an intervening weekend off. *Sleep*. 2008; 31:1639–45. [PubMed: 19090319]
155. Smith MR, Fogg LF, Eastman CI. Practical interventions to promote circadian adaptation to permanent night shift work: Study 4. *J Biol Rhythms*. 2009; 24:161–72. [PubMed: 19346453]
156. Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. *Behav Brain Res*. 1996; 73:131–34. [PubMed: 8788490]
157. Arendt J, Skene DJ. Melatonin as a chronobiotic. *Sleep Med Rev*. 2005; 9:25–39. [PubMed: 15649736]
158. Rajaratnam SM, Dijk DJ, Middleton B, Stone BM, Arendt J. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. *J Clin Endocrinol Metab*. 2003; 88:4303–09. [PubMed: 12970302]
159. Arendt J, Rajaratnam SM. Melatonin and its agonists: An update. *Br J Psychiatry*. 2008; 193:267–69. [PubMed: 18827285]
160. Wirz-Justice A, Armstrong SM. Melatonin: Nature's soporific? *J Sleep Res*. 1996; 5:137–41. [PubMed: 8795816]
161. Munday K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. *Sleep*. 2005; 28:1271–78. [PubMed: 16295212]

162. Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. *J Clin Endocrinol Metab.* 2010; 95:3325–31. [PubMed: 20410229]
163. Dagan Y, Yovel I, Hallis D, Eisenstein M, Raichik I. Evaluating the role of melatonin in the long-term treatment of delayed sleep phase syndrome (DSPS). *Chronobiol Int.* 1998; 15:181–90. [PubMed: 9562922]
164. Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effects of exogenous melatonin on delayed sleep phase syndrome. *Psychosom Med.* 2001; 63:40–48. [PubMed: 11211063]
165. Revell VL, Burgess HJ, Gazda CJ, Smith MR, Fogg LF, Eastman CI. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. *J Clin Endocrinol Metab.* 2006; 91:54–59. [PubMed: 16263827]
166. Nagtegaal JE, Kerkhof GA, Smits MG, Swart ACW, van der Meer YG. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. *J Sleep Res.* 1998; 7:135–43. [PubMed: 9682186]
167. McArthur AJ, Lewy AJ, Sack RL. Non-24-hour sleep-wake syndrome in a sighted man: Circadian rhythm studies and efficacy of melatonin treatment. *Sleep.* 1996; 19:544–53. [PubMed: 8899933]
168. Siebler M, Steinmetz H, Freund HJ. Therapeutic entrainment of circadian rhythm disorder by melatonin in a non-blind patient. *J Neurol.* 1998; 245:327–28. [PubMed: 9669484]
169. Arendt J, Aldhous M, Wright J. Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment. *Lancet.* 1988; 1:772–73. [PubMed: 2895305]
170. Sack RL, Brandes R, deJongh L, Pen S, Nordstrom S, Lewy AJ. Melatonin entrains free-running circadian rhythms in a totally blind person. *Sleep.* 1999; 22:S138–S39.
171. Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. *New Engl J Med.* 2000; 343:1070–77. [PubMed: 11027741]
172. Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD. Melatonin administration to blind people: Phase advances and entrainment. *J Biol Rhythms.* 1991; 6:249–61. [PubMed: 1773095]
173. Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J. Melatonin administration can entrain the free-running circadian system of blind subjects. *J Endocrinol.* 2000; 164:R1–R6. [PubMed: 10607943]
174. Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. *Br Med J.* 1986; 292:1170. [PubMed: 3085768]
175. Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. *J Biol Rhythms.* 1997; 12:604–17. [PubMed: 9406036]
176. Skene D, Deacon S, Arendt J. Use of melatonin in circadian rhythm disorders and following phase shift. *Acta Neurobiol Exp (Wars).* 1996; 56:359–62. [PubMed: 8787196]
177. Arendt J. Jet-lag and shift work: (2). Therapeutic use of melatonin. *J R Soc Med.* 1999; 92:402–05. [PubMed: 10656005]
178. Arendt J, Marks V. Jet lag and melatonin. *Lancet.* 1986; 328:698–99. [PubMed: 2876180]
179. Lewy AJ, Ahmed S, Jackson JML, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. *Chronobiol Int.* 1992; 9:380–92. [PubMed: 1394610]
180. Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. *J Physiol.* 2008; 586(2):639–47. [PubMed: 18006583]
181. Sharkey KM, Eastman CI. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. *Am J Physiol Regul Integr Comp Physiol.* 2002; 282:R454–R63. [PubMed: 11792655]
182. Krystal AD, Edinger J, Wohlgemuth W, Marsh GR. Sleep in peri-menopausal and post-menopausal women. *Sleep Med Rev.* 1998; 2:243–53. [PubMed: 15310495]
183. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep.* 1997; 20:705–06. [PubMed: 9406321]

184. Pamidi S, Wroblewski K, Broussard J, et al. Obstructive sleep apnea in young lean men: impact on insulin sensitivity and secretion. *Diabetes Care*. 2012; 35:2384–9. [PubMed: 22912423]

Table 1

International Classification of Sleep Disorders categories of Circadian Rhythm Sleep Disorders with typical clinical features.

Disorder	Clinical features
Delayed sleep phase type	Sleep and wake times are delayed (later) compared to normal individuals and desired times, with striking inability to fall asleep and wake earlier at the desired time
Advanced sleep phase type	Sleep and wake times advanced (earlier) compared to normal individuals and desired times, with striking inability to remain awake and remain asleep until the desired time
Irregular sleep-wake type	Unrecognizable pattern and disorganized sleep and wake times, with insomnia and/or excessive daytime sleepiness
Free running type	Gradually delayed bedtime by 1-2 hours a day with insomnia and inability to wake in the morning
Jet lag type	Inability to fall asleep and wake at times compatible with desired times due to recent travel to new time zone.
Shift work type	Inability to fall sleep (during the day) and remain awake (at night) at times required for work schedule.

Table 2

Components of a sleep history.

1. Define the specific sleep problem

What is the primary complaint?

2. Assess the clinical course

When did the sleep problem begin?

3. Examine recent factors/changes that can affect sleep

Recent medical, psychiatric, and surgical history, recent changes in medications?

*Recent travel history (crossing time-zones), changes in work hours?

4. Evaluate sleep/wakefulness patterns

*When does the patient get into bed, how long does it take them to fall asleep?

*What is the final rising time?

How many times during the night does the patient awaken, for what reasons (to void, environmental, unknown), how long does it take them to fall back asleep?

*Regularity of bedtimes and wake times (including work days vs. days off)?

5. Evaluate sleep hygiene

What is the sleep environment (noise, light, bed partner)?

What is the pre-bedtime routine (including medications)?

What are the current medications that could impact sleep or daytime sleepiness (including caffeine, alcohol, sedatives)

6. Obtain information from the patient or bed partner about signs associated with specific sleep disorders

Is there snoring, gasping, morning headache, limb movements?

7. Evaluate the impact of the disorder on the patient

What is the patient's daytime functioning (daytime sleepiness, napping, job performance)?

*Key questions for CRSD diagnosis.

Table 3
Questionnaires that can be useful in evaluating patients with possible sleep disorders

Questionnaire	Measurement
Morningness-Eveningness Questionnaire ¹¹⁹ and/or Munich Chronotype Questionnaire ¹²⁰	The typical or desired timing for activity and sleep across the 24-hour day
Pittsburgh Sleep Quality Index ¹²¹	Quality, timing, duration and disturbance of sleep in the past month
Beck Depression Inventory ¹²⁴	Determine co morbid depressive mood disorder
Epworth Sleepiness Scale ¹²³	Excessive daytime sleepiness
Insomnia Severity Index ¹²⁵	Type, severity, and functional consequences of insomnia
Functional Outcomes of Sleep Questionnaire ¹²²	Difficulty performing daily activity due to sleepiness